20/20 HealthCare Partners
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact

20/20 HealthCare Partners

14 Feb2022

Technology-Driven Precision Medicine Company Variantyx Secures $41.5M in Funding

Written by 2020HCP.com. Posted in News

FRAMINGHAM, Mass., Feb. 14, 2022 /PRNewswire/ — Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.5M in funding. The series C-2 funding round, led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech, will be used to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.

  • Continue Reading
24 Jan2022

SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors

Written by 2020HCP.com. Posted in News

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SQZ-eAPC-HPV, authorizing the company to proceed with initiating a Phase 1/2 clinical trial of the novel cell therapy candidate. The company plans to initiate its COMMANDER-001 Phase 1/2 clinical trial of SQZ-eAPC-HPV in patients who have HPV16+ solid tumors, including head and neck, cervical, and anal cancers, and have progressed following standard therapies.

  • Continue Reading
13 Jan2022

Patients Can Now Use A Vive Flow To Access Healthcare In VR

Written by 2020HCP.com. Posted in News

Bobby Carlton in News

HTC is bringing physical therapy, occupational therapy, and pain management treatments to the metaverse.

HTC VIVE is partnering with XRHealth to bring healthcare into the metaverse in the form of virtual medical rooms where patients can receive physical therapy, occupational therapy, and pain management treatments. These digital facilities will be accessible in VR using either a VIVE Focus 3 or VIVE Flow headset, depending on if you are the doctor or the patient.

  • Continue Reading
04 Jan2022

Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Targeting Monoclonal Antibody

Written by 2020HCP.com. Posted in News

BEDFORD Mass. – January 4, 2022 – Verseau Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for its lead investigational product candidate, VTX-0811, a monoclonal antibody that binds to P-selectin glycoprotein ligand-1 (PSGL-1). VTX-0811 repolarizes macrophages, leading to coordinated anti-tumor immune responses. The FDA has completed its 30-day safety review and granted approval for the company to proceed with the proposed first-in-human clinical trial of VTX-0811.

  • Continue Reading
09 Dec2021

SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

Written by 2020HCP.com. Posted in News

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented interim results from the highest-dose cohort of its ongoing Phase 1/2 clinical trial of lead Antigen Presenting Cell (APC) therapy candidate targeting Human Papillomavirus positive (HPV16+) solid tumors at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress. Of the five patients in this cohort evaluable for efficacy, one checkpoint refractory head-and-neck cancer patient showed a radiographic response and symptomatic improvement. The target lesion demonstrated a complete response at both radiographic assessments. At the most recent assessment, the major oropharyngeal lesion demonstrated continued improvement upon physical examination; however, a new dermal lesion was detected. The investigational therapy was well-tolerated, and no dose-limiting toxicities were observed as of October 8, 2021.

  • Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • ...
  • 12

Latest News

  • SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting June 21, 2022
  • SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors April 28, 2022
  • SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo April 11, 2022
  • SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes April 5, 2022
  • Verizon, Bloomberg Media, Zixi & AWS test how 5G & edge compute can transform broadcast February 23, 2022

20/20 HealthCare Partners | 2000 Commonwealth Ave, Suite 200, Auburndale, MA 02466 | Contact Us

Copyright © 2019
  • Home
  • What Differentiates 20/20 HCP
  • Team
  • Companies
    • Companies
    • Exits
  • News
  • Contact